STOCK TITAN

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Akebia Therapeutics (NASDAQ: AKBA) will release its financial results for the fourth quarter and full-year ended December 30, 2022, on March 9, 2023, before market opening. The company aims to improve the lives of those affected by kidney disease and plans to host a conference call at 8:30 a.m. ET on the same day to discuss its results and business updates. Interested parties can access the call via a registration link or through a live webcast on Akebia's website. The company emphasizes its commitment to innovation in kidney disease therapeutics.

Positive
  • Scheduled release of financial results on March 9, 2023.
  • Conference call planned to discuss business highlights.
Negative
  • None.

Akebia to Host Conference Call

CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year ended December 30, 2022 on Thursday, March 9 prior to the open of financial markets.

Akebia will host a conference call on Thursday, March 9 at 8:30 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this Registration Link and you will be provided with dial in details. To avoid delays, we encourage dialing into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-discuss-recent-business-highlights-301759965.html

SOURCE Akebia Therapeutics

FAQ

When will Akebia Therapeutics report its financial results?

Akebia Therapeutics will report its financial results on March 9, 2023.

What time is the conference call for Akebia's financial results?

The conference call is scheduled for 8:30 a.m. ET on March 9, 2023.

How can I access the Akebia Therapeutics conference call?

You can access the conference call via a registration link or through a live webcast on Akebia's website.

What is the purpose of Akebia Therapeutics?

Akebia Therapeutics focuses on developing therapeutics for people impacted by kidney disease.

Akebia Therapeutics, Inc.

NASDAQ:AKBA

AKBA Rankings

AKBA Latest News

AKBA Stock Data

404.73M
207.87M
2.09%
27.29%
7.05%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE